Zika virus Pathogenesis and Targeted Intervention Strategies.
- 1Department of Clinical Microbiology and Immunology, College of Pharmacy and Medical Laboratory, Army Medical University (Third Military Medical University), Chongqing 400038, China.
- 2School of Medicine, Chongqing University, Chongqing 400030, China.
Abstract
Zika virus (ZIKV), a mosquito-borne member of the Flaviviridae family, is primarily transmitted via the bite of Aedes aegypti mosquitoes but can also be spread through sexual contact and vertical transmission. Infection with ZIKV causes Zika fever and Guillain-Barré syndrome (GBS); more importantly, maternal infection during pregnancy can result in severe neurodevelopmental disorders, such as fetal microcephaly. Although the World Health Organization declared the Zika outbreak a Public Health Emergency of International Concern (PHEIC) in 2016, and extensive research has since been conducted, no approved vaccines or therapeutic drugs are currently available. Recent studies have shown that various ZIKV-encoded proteins participate in host-barrier breaching, regulation of tissue tropism, interference with neurodevelopment, mediation of neurotoxicity, and evasion of type I interferon (IFN-I) immune responses, thereby advancing the development of vaccines and antiviral drugs targeting viral proteins. However, the complete mechanisms by which viral proteins synergistically mediate pathogenesis, the clinical significance of antibody-dependent enhancement (ADE) and its prevention and control strategies, and the practical barriers to clinical translation of protein-targeted interventions have not been systematically elucidated. This review is structured around viral proteins as a central framework: it summarizes the molecular mechanisms by which multiple ZIKV proteins synergistically regulate pathogenic processes; reviews the current research basis and response strategies for flavivirus ADE, and outlines unresolved scientific questions; and discusses progress in vaccines and antiviral drugs targeting viral proteins, with emphasis on evidence gaps and clinical translation barriers. By integrating existing findings and unresolved scientific questions, this review provides a research-gap-oriented theoretical reference for basic ZIKV research and clinical translation of prevention and control strategies.
Related
- Prior Dengue Virus Exposure is Associated with Enhanced Zika Virus-Specific ADCC Activity in a Longitudinal Human Cohort
- Early Detection and Response to the First Imported Case of Zika Virus Disease — Hainan Province, China, 2025
- Maternal adaptation to caring for a child with congenital Zika virus syndrome.
- Kinetics and specificity of orthoflaviviruses NS1 IgG after Zika virus infection in Yellow fever and dengue immunized individuals: a memory recall hypothesis
- Coevolutionary constraints of Zika virus nonstructural protein 5 replication and interferon antagonism activities
BibTeX
@article{suo2026zika,
title = {{Zika virus Pathogenesis and Targeted Intervention Strategies.}},
author = {Liangpeng Suo and Haizhen Fan and Qiong Wu and Xingyang Wei and Hanxi Xiao and Beibei Fu and Xuhu Mao and Xiaoyuan Lin},
journal = {Viruses},
year = {2026},
month = oct,
doi = {10.3390/v18101085},
url = {https://europepmc.org/article/MED/42944005},
note = {CC BY},
}
RIS
TY - JOUR
TI - Zika virus Pathogenesis and Targeted Intervention Strategies.
AU - Liangpeng Suo
AU - Haizhen Fan
AU - Qiong Wu
AU - Xingyang Wei
AU - Hanxi Xiao
AU - Beibei Fu
AU - Xuhu Mao
AU - Xiaoyuan Lin
PY - 2026
DA - 2026/10/01
JO - Viruses
DO - 10.3390/v18101085
UR - https://europepmc.org/article/MED/42944005
AB - Zika virus (ZIKV), a mosquito-borne member of the Flaviviridae family, is primarily transmitted via the bite of Aedes aegypti mosquitoes but can also be spread through sexual contact and vertical transmission. Infection with ZIKV causes Zika fever and Guillain-Barré syndrome (GBS); more importantly, maternal infection during pregnancy can result in severe neurodevelopmental disorders, such as fetal microcephaly. Although the World Health Organization declared the Zika outbreak a Public Health Emergency of International Concern (PHEIC) in 2016, and extensive research has since been conducted, no approved vaccines or therapeutic drugs are currently available. Recent studies have shown that various ZIKV-encoded proteins participate in host-barrier breaching, regulation of tissue tropism, interference with neurodevelopment, mediation of neurotoxicity, and evasion of type I interferon (IFN-I) immune responses, thereby advancing the development of vaccines and antiviral drugs targeting viral proteins. However, the complete mechanisms by which viral proteins synergistically mediate pathogenesis, the clinical significance of antibody-dependent enhancement (ADE) and its prevention and control strategies, and the practical barriers to clinical translation of protein-targeted interventions have not been systematically elucidated. This review is structured around viral proteins as a central framework: it summarizes the molecular mechanisms by which multiple ZIKV proteins synergistically regulate pathogenic processes; reviews the current research basis and response strategies for flavivirus ADE, and outlines unresolved scientific questions; and discusses progress in vaccines and antiviral drugs targeting viral proteins, with emphasis on evidence gaps and clinical translation barriers. By integrating existing findings and unresolved scientific questions, this review provides a research-gap-oriented theoretical reference for basic ZIKV research and clinical translation of prevention and control strategies.
SN - 1999-4915
ER -